Last $5.19 USD
Change Today +0.01 / 0.19%
Volume 249.2K
As of 8:10 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Open
$5.17
Previous Close
$5.18
Day High
$5.34
Day Low
$5.08
52 Week High
07/18/14 - $5.77
52 Week Low
08/19/13 - $2.05
Market Cap
260.4M
Average Volume 10 Days
448.9K
EPS TTM
$0.05
Shares Outstanding
50.2M
EX-Date
--
P/E TM
100.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

315 Employees
Last Reported Date: 05/8/14
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $557.0K
Chief Financial Officer
Total Annual Compensation: $305.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $92.5K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $72.5K
Chief Scientific Officer
Total Annual Compensation: $331.6K
Compensation as of Fiscal Year 2013.

neogenomics inc (NEO) Key Developments

Neogenomics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Full Year of 2014

Neogenomics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company’s net revenue was $20,670,000 against $15,603,000 a year ago. Income from operations was $578,000 against $505,000 a year ago. Income before taxes was $325,000 against $273,000 a year ago. Net income was $274,000 or $0.01 basic and diluted per share against $273,000 or $0.01 basic and diluted per share a year ago. EBITDA was $1,919,000 against $1,623,000 a year ago. Adjusted EBITDA (non-GAAP) was $2,116,000 against $1,825,000 a year ago. The company record $4.3 million of cash flow from operations in the quarter. For the six months, the company’s net revenue was $38,852,000 against $31,260,000 a year ago. Income from operations was $972,000 against $810,000 a year ago. Income before taxes was $454,000 against $293,000 a year ago. Net income was $376,000 or $0.01 basic and diluted per share against $276,000 or $0.01 basic and diluted per share a year ago. EBITDA was $3,520,000 against $2,973,000 a year ago. Adjusted EBITDA (non-GAAP) was $3,801,000 against $3,619,000 a year ago. Net cash provided by operating activities was $5,298,000 against $533,000 a year ago. For the third quarter 2014, the company expects revenue of $22.0 million to $23.5 million and EPS of $0.01 to $0.01. For the full year 2014, the company expects revenue to be $83.0 million to $86.0 million with earnings per share of $0.00 to $0.03.

NeoGenomics, Inc. Launches 23 New NeoTYPE(TM) Cancer Profiles Based on Next-Generation Sequencing

NeoGenomics Inc. announced it has launched 23 new NeoTYPE(TM) Cancer Profiles based on next-generation sequencing (NGS). These new advanced cancer-profiling tools offer oncologists and pathologists a more targeted and comprehensive ability to tailor cancer testing to an individual patient's needs than has ever been available before. Next-generation sequencing is an advanced molecular testing approach that is used to more precisely detect a variety of mutations using smaller amounts of tissue. As a result, NeoGenomics will accept fine needle aspirate and other minute samples for testing. In March, NeoGenomics announced that it was the first to offer plasma-based Next-generation tests for hematologic neoplasms. This testing can allow patients to avoid a bone marrow biopsy, and allow clinicians to monitor tumor load and detect emerging subclones. NeoTYPE(TM) plasma-based testing using NGS is now available for AML Prognostic, CLL Prognostic, JMML, Lymphoma, MDS/CMML, MPN, and a comprehensive, 54-gene Myeloid Disorders Profile. Similarly, the NeoTYPE(TM) solid tumor tests are designed to provide precise and complete coverage of 'actionable' molecular abnormalities found specifically in the tested tumor. NeoTYPE(TM) solid tumor cancer testing is available for Brain, Breast, Cervix, Colorectal, Endometrial, Esophageal, Gastrointestinal Stromal (GIST), Lung, Melanoma, Ovarian, Soft Tissue, Thyroid, and Other Solid Tumors.

Neogenomics Inc.(NasdaqCM:NEO) dropped from Russell 2000 Index

Neogenomics Inc. will be removed from the Russell 2000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $5.19 USD +0.01

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $10.15 USD -0.19
Foundation Medicine Inc $22.23 USD -0.29
Genomic Health Inc $25.54 USD +0.06
Response Genetics Inc $0.77 USD -0.0052
Rosetta Genomics Ltd $3.86 USD -0.0599
View Industry Companies
 

Industry Analysis

NEO

Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 3.5x
Price/Book 11.2x
Price/Cash Flow 121.9x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit www.neogenomics.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.